Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Spain's Universal Diagnostics Bets on Cell-Free DNA Methylation for Early-Stage Cancer Detection

Spain's Universal Diagnostics Bets on Cell-Free DNA Methylation for Early-Stage Cancer Detection

Sep 24, 2020
|
John Gilmore
Premium

NEW YORK – Spanish cancer IVD developing Universal Diagnostics has shifted it commercial strategy from using mass spectrometry for early cancer detection to a liquid biopsy approach that identifies DNA methylation biomarkers to detect precancerous cells in patient blood samples that may indicate early-stage colorectal cancer (CRC) or other tumors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

To Keep Up

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

On the Rise in the City

The New York Times reports that a new viral variant of concern has been identified in New York City.

Nature Studies Present Single-Cell Map of Cell Cycle, Approach Identifies Cancer Treatment Resistance Pathways, More

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

What's Popular?

In Liquid Biopsy

  1. Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

    Premium

  2. Guardant Health Q4 Revenues Up 25 Percent

  3. Biocartis Reports 15 Percent Rise in 2020 Revenues

  4. Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test

  5. Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.